Friday, July 31, 2026

How Rasmotinib and PHI-501 Could Revolutionize Cancer Treatment: Insights from Bio Europe Spring 2026

Pharos iBio showcases its cancer treatments at Bio Europe Spring 2026, seeking global partnerships for Rasmotinib and PHI-501.

Palantir’s 24% Drop in 5 Days Linked to DoD Budget Cuts, Despite AI Sector Growth

Palantir Technologies' stock dropped 10% after DoD budget cuts, highlighting its reliance on government contracts amidst an AI boom.

First Harvest from North Korea’s Massive Greenhouse: What It Means for Local Communities

North Korea celebrates its first vegetable harvest from the Sinuiju Greenhouse Complex, showcasing disaster recovery and improved living conditions.

Tag: biosimilars

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Celltrion’s Omlyclo Gains Traction in Italy, Reinforcing Direct Sales Strategy as Growth Expected to Accelerate

Celltrion expands its biosimilar supply in Italy, enhancing its competitiveness in the European pharmaceutical market.

Celltrion Files for European Approval of Cosentyx Biosimilar, Targets $6.7 Billion Market

Celltrion has filed for European approval of its CT-P55 biosimilar for autoimmune diseases, aiming for early market entry and expansion.

How Celltrion’s Truxima Dominates the U.S. Rituximab Market: A 4-Month Winning Streak

Celltrion's Truxima leads the U.S. rituximab market for four months, gaining FDA interchangeability status, boosting growth prospects.

South Korea Eases Phase 3 Trial Requirements for Biosimilars Following U.S. and EU… Early Data Becomes Key Battleground

South Korea's MFDS eases Phase 3 trial requirements for biosimilars, aligning with global trends, enhancing early comparability importance.

How Celltrion’s Omlyclo Achieved 16% Market Share in Europe: A Game-Changer for Biologics

Celltrion's biosimilars gain market share in Europe, with Omlyclo leading in Spain and Vegzelma maintaining strong presence amid competition.

Interview: Huons’ PanGen Bets on ‘Development-Focused CDMO’ Strategy Built on Biosimilar Experience

South Korea's PanGen CDMO emphasizes development expertise and tailored services, enhancing drug development support for clients.

Celltrion Launches New Autoimmune Drug Avtozma in Japan

Celltrion launches Avtozma for autoimmune diseases in Japan, expanding its product portfolio and strengthening market presence.

Celltrion’s Steqeyma IV Approval: What This Means for Celltrion’s Growth in Japan’s Autoimmune Drug Market

Celltrion's Steqeyma IV formulation gains approval in Japan, expanding treatment for Crohn's disease and enhancing market competitiveness.

Truxima: How the First Korean Biosimilar Achieved 35.8% Market Share in the U.S.!

Celltrion’s Truxima becomes South Korea's first biosimilar to lead U.S. prescription market, boosted by tariff exemptions and strong growth.

How Celltrion’s Local Production Strategy Eliminates U.S. Drug Tariffs Influence

Celltrion resolves tariff impacts on U.S. sales, boosting local production and growth opportunities for its biosimilars, including Zymfentra.

Samchundang Pharm Announces 250 Billion KRW Stake Sale…Expectations Rise for Future Growth

Samchundang Pharm's CEO plans a 2.5 billion KRW share sale for tax purposes, hinting at significant news and future growth in pharma.

Celltrion’s 1 Trillion KRW Investment: A Game Changer for Biopharmaceutical Production by 2030

Celltrion plans a major expansion with over 1 trillion KRW investment, boosting production capacity for biosimilars and new drugs by 2030.

Why Celltrion’s STEQEYMA Auto-Injector is a Game Changer for Autoimmune Patients in North America

Celltrion expands its Steqeyma auto-injector lineup in Canada, enhancing market competitiveness and patient accessibility in North America.

Celltrion’s Breakthrough: Why Vegzelma and Herzuma Lead in Japan’s Oncology Market

Celltrion's cancer treatments dominate the Japanese market, with Vegzelma and Herzuma capturing significant shares, showcasing strong growth.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.